The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
XRay Vision: A phase 3 study of xevinapant plus radiotherapy (RT) for high-risk, cisplatin-ineligible patients with resected, locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
 
Robert L. Ferris
Stock and Other Ownership Interests - Novasenta
Consulting or Advisory Role - Achilles Therapeutics; Adagene; Aduro Biotech; Bicara Therapeutics; Bristol-Myers Squibb; Cantenion; Coherus Biosciences; Eterna Therapeutics; Everest Clinical Research; F. Hoffmann LaRoche; Genocea Biosciences; Hookipa Pharma; Instil Bio; Kowa Research Institute; Lifescience Dynamics; Macrogenics; MeiraGTx; Merck; Mirati Therapeutics; Mirror Biologics; Nanobiotix; Novartis; Novasenta; Numab; OncoCyte; Pfizer; PPD; Rakuten Medical; Sanofi; Seagen; SIRPant Immunotherapeutics; VIR Biotechnology; Zymeworks; Zymeworks
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck; Novasenta; Tesaro
 
Hisham Mohamed Mehanna
Employment - Warwickshire Head and Neck Clinic
Leadership - Warwickshire Head and Neck Clinic; Warwickshire Head and Neck Clinic (I)
Stock and Other Ownership Interests - Warwickshire Head and Neck Clinic
Honoraria - AstraZeneca
Speakers' Bureau - Merck; MSD; Sanofi Pasteur
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); MSD (Inst); Sanofi Pasteur (Inst)
 
Jonathan Daniel Schoenfeld
Stock and Other Ownership Interests - Doximity; Immunitas
Consulting or Advisory Role - ACI Clinical; Astellas Pharma; Castle Biosciences; Debiopharm Group; Genentech; Immunitas; Merck KGaA; SIRPant Immunotherapeutics; Stimit
Research Funding - Bristol-Myers Squibb; EMD Serono/Merck; Merck; Regeneron
Expert Testimony - Heidell, Pittoni, Murphy & Bach; Kline & Specter P.C.
 
Makoto Tahara
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; Lilly; Merck Serono; MSD; Ono Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Genmab; Janssen; Lilly; MSD; Nanobiotix; Nektar; Ono Pharmaceutical; Pfizer; Rakuten Medical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Rakuten Medical (Inst)
 
Sue S. Yom
Research Funding - Bristol-Myers Squibb (Inst); EMD Serono (Inst); Merck (Inst)
 
Robert I. Haddad
Employment - Dana-Farber Cancer Institute
Leadership - NCCN
Consulting or Advisory Role - Achilles Therapeutics; AstraZeneca; Bayer; BioNTech; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Coherus Biosciences; Eisai; EMD Serono; Genentech; Genmab; Gilead Sciences; GlaxoSmithKline; Immunomic Therapeutics; Loxo; Merck; Mirati Therapeutics; Pfizer; Vaccinex
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Kura Oncology (Inst); Merck (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Other Relationship - Boehringer Ingelheim; ISA Pharmaceuticals; Nanobiotix
 
Andre Koenig
Employment - Merck KGaA
 
Satu Maaria Salmio
Employment - Merck KGaA
 
Marcis Bajars
Employment - Merck KGaA
 
Christophe Le Tourneau
Honoraria - Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Merck Serono; MSD; Nanobiotix; Novartis; Rakuten Medical; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Merck Serono; MSD; Nanobiotix; Roche
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD